0001493152-21-027163.txt : 20211104 0001493152-21-027163.hdr.sgml : 20211104 20211103182621 ACCESSION NUMBER: 0001493152-21-027163 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211103 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAVmed Inc. CENTRAL INDEX KEY: 0001624326 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 471214177 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37685 FILM NUMBER: 211377044 BUSINESS ADDRESS: STREET 1: ONE GRAND CENTRAL PLACE STREET 2: SUITE 4600 CITY: NEW YORK STATE: NY ZIP: 10165 BUSINESS PHONE: 212-949-4319 MAIL ADDRESS: STREET 1: ONE GRAND CENTRAL PLACE STREET 2: SUITE 4600 CITY: NEW YORK STATE: NY ZIP: 10165 FORMER COMPANY: FORMER CONFORMED NAME: PAXmed Inc. DATE OF NAME CHANGE: 20141105 8-K 1 form8-k.htm
0001624326 false 0001624326 2021-11-03 2021-11-03 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2021-11-03 2021-11-03 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2021-11-03 2021-11-03 0001624326 PAVM:SeriesWWarrantsToPurchaseCommonStockMember 2021-11-03 2021-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 3, 2021

 

PAVMED INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-37685   47-1214177

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

One Grand Central Place, Suite 4600, New York, New York   10165
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212) 949-4319

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   PAVM   The Nasdaq Stock Market LLC
Series Z Warrants to Purchase Common Stock   PAVMZ   The Nasdaq Stock Market LLC
Series W Warrants to Purchase Common Stock   PAVMW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 3, 2021, PAVmed Inc. (“PAVmed”) and its major subsidiary Lucid Diagnostics Inc. (“Lucid,” and together with PAVmed, the “Companies”), issued a press release announcing that the Companies will host a joint business update conference call on Tuesday, November 16, 2021, at 4:30 PM EDT. Attached as Exhibit 99.1 to this Current Report is a copy of the press release, which is incorporated herein by reference.

 

The information furnished under this Item 2.02, including the exhibits related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any disclosure document of PAVmed, except as shall be expressly set forth by specific reference in such document.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
     
99.1   Press release.
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 3, 2021

 

  PAVMED INC.
     
  By: /s/ Dennis M. McGrath
    Dennis M. McGrath
    President and Chief Financial Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021

 

Company conference call and webcast at 4:30PM EDT

 

NEW YORK, November 3, 2021 (BUSINESS WIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company today announced that the companies will host a joint business update conference call on Tuesday, November 16, 2021, at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the companies, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the companies’ Chief Financial Officer, will discuss the companies’ third quarter 2021 financial results.

 

To access the conference call, U.S.-based listeners should dial 877-407-3982 and international listeners should dial 201-493-6780. All listeners should provide the operator with the conference call name “PAVmed, Inc. Business Update Conference Call” to join. Individuals interested in listening to the live conference call via webcast may do so by visiting the investor relations section of the Company’s website at www.pavmed.com.

 

Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 from within the U.S. or 412-317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 1374402. The webcast will be available for replay on the investor relations section of the Company’s website at www.pavmed.com.

 

About PAVmed & Lucid

 

PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure™ Esophageal Ablation Device with Caldus™ Technology. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. Its Minimally Invasive Interventions division markets its CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy (PortIO™ Implantable Intraosseous Vascular Access Device and NextFlo™ Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube.

 

 

 

 

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

 

Forward-Looking Statements

 

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, the ability to complete the initial public offering of Lucid; volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company’s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

Contacts:

 

Investors

Lisa DeScenza

LaVoieHealthScience

(617) 351-0243

ldescenza@lavoiehealthscience.com

 

Media

Kristi Bruno

LaVoieHealthScience

(617) 865-3940

PAVmed@lavoiehealthscience.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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ⅅ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end EX-101.SCH 4 pavm-20211103.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 pavm-20211103_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 pavm-20211103_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, Par Value $0.001 Per Share Series Z Warrants to Purchase Common Stock Series W Warrants to Purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 pavm-20211103_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001624326 2021-11-03 2021-11-03 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2021-11-03 2021-11-03 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2021-11-03 2021-11-03 0001624326 PAVM:SeriesWWarrantsToPurchaseCommonStockMember 2021-11-03 2021-11-03 iso4217:USD shares iso4217:USD shares 0001624326 false 8-K 2021-11-03 PAVMED INC. DE 001-37685 47-1214177 One Grand Central Place Suite 4600 New York NY 10165 (212) 949-4319 false false false false Common Stock, Par Value $0.001 Per Share PAVM NASDAQ Series Z Warrants to Purchase Common Stock PAVMZ NASDAQ Series W Warrants to Purchase Common Stock PAVMW NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 03, 2021
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 03, 2021
Entity File Number 001-37685
Entity Registrant Name PAVMED INC.
Entity Central Index Key 0001624326
Entity Tax Identification Number 47-1214177
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One One Grand Central Place
Entity Address, Address Line Two Suite 4600
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10165
City Area Code (212)
Local Phone Number 949-4319
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, Par Value $0.001 Per Share  
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol PAVM
Security Exchange Name NASDAQ
Series Z Warrants to Purchase Common Stock  
Title of 12(b) Security Series Z Warrants to Purchase Common Stock
Trading Symbol PAVMZ
Security Exchange Name NASDAQ
Series W Warrants to Purchase Common Stock  
Title of 12(b) Security Series W Warrants to Purchase Common Stock
Trading Symbol PAVMW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 4 96 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm pavm-20211103.xsd pavm-20211103_def.xml pavm-20211103_lab.xml pavm-20211103_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "pavm-20211103_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pavm-20211103_lab.xml" ] }, "presentationLink": { "local": [ "pavm-20211103_pre.xml" ] }, "schema": { "local": [ "pavm-20211103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 3, "memberStandard": 0, "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20211103", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-11-03to2021-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://pavmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-11-03to2021-11-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "PAVM_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value $0.001 Per Share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://pavmed.com/20211103", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "PAVM_SeriesWWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series W Warrants to Purchase Common Stock" } } }, "localname": "SeriesWWarrantsToPurchaseCommonStockMember", "nsuri": "http://pavmed.com/20211103", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "PAVM_SeriesZWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z Warrants to Purchase Common Stock" } } }, "localname": "SeriesZWarrantsToPurchaseCommonStockMember", "nsuri": "http://pavmed.com/20211103", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001493152-21-027163-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-027163-xbrl.zip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